Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD40 agonist monoclonal antibody ABBV-927

An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, ABBV-927 binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:agonistic anti-CD40 monoclonal antibody ABBV-927
anti-CD40 monoclonal antibody ABBV-927
Code name:ABBV-927
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search